GoodRx Announces Proposed Refinancing of First Lien Credit Facilities
23 January 2024 - 6:15AM
Business Wire
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the
“Company”), the leading destination for prescription savings, today
announced its intention to refinance its first lien credit
facilities.
The Company is seeking to refinance its first lien term loan
facility and concurrently amend its revolving credit facility to
extend the maturity date. The terms of the proposed refinancing, if
any, will be disclosed upon the completion of the transaction,
which is expected to occur during the Company’s first fiscal
quarter of 2024.
The proposed refinancing transaction is subject to the
occurrence of the effectiveness of definitive documentation for the
credit facilities as well as customary closing conditions, and is
subject to market and other conditions. There can be no assurance
that the refinancing will occur, or, if it does, the terms of the
refinancing.
About GoodRx
GoodRx is the leading destination for prescription savings. We
offer consumers free access to transparent and lower prices for
generic and brand medications, as well as comprehensive healthcare
research and information. We also equip healthcare providers with
efficient ways to find and prescribe affordable medications. Since
2011, GoodRx has helped consumers save more than $65 billion and is
one of the most downloaded medical apps over the past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the proposed refinancing and our plans with respect
thereto. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, risks
related to the availability of capital on favorable terms or at
all, as well as the other important factors discussed in the
section entitled “Risk Factors” of our Annual Report on Form 10-K
for the fiscal year ended December 31, 2022, as updated by our
Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2023, and in our other filings with the SEC. The
forward-looking statements in this press release are based upon
information available to us as of the date of this press release,
and while we believe such information forms a reasonable basis for
such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently
uncertain and investors are cautioned not to unduly rely upon these
statements. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240122460101/en/
Investor Contact GoodRx Whitney Notaro
wnotaro@goodrx.com
Press Contact GoodRx Lauren Casparis
lcasparis@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Apr 2024 to May 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From May 2023 to May 2024